Botswana TDF/FTC Oral HIV Prophylaxis Trial (TDF2)

Clinical Trial ID NCT00448669

Rank	Title	Journal	Year	PubWeight™‹?›
1	Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.	N Engl J Med	2012	20.03
2	Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.	Lancet	2011	6.91
3	Persisting with prevention: the importance of adherence for HIV prevention.	Emerg Themes Epidemiol	2008	1.71
4	Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.	PLoS One	2014	1.12
5	CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis.	AIDS	2014	1.08
6	Implications of HIV PrEP trials results.	AIDS Res Hum Retroviruses	2010	0.92
7	Normal laboratory reference intervals among healthy adults screened for a HIV pre-exposure prophylaxis clinical trial in Botswana.	PLoS One	2014	0.89
8	Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010.	AIDS Behav	2015	0.84
9	Knowledge, Attitudes, and Experiences of HIV Pre-Exposure Prophylaxis (PrEP) Trial Participants in Botswana.	World J AIDS	2015	0.79
10	HIV pre-exposure prophylaxis (PrEP)--a quantitative ethics appraisal.	PLoS One	2011	0.78